Chemotherapeutic Agents

Over the past decade, there has been a paradigm shift in the treatment of cancer, driven by advances in personalized medicine and immuno-oncology. According to the WHO, cancer was the second leading cause of death in 2015, responsible for 8.8 million deaths globally. From 2011-2015, 42 new cancer medicines were launched globally, but the availability of newly launched agents differs substantially by geography, with the highest number of novel agents being available in the United States and Germany. The pipeline of oncology drugs in clinical development has expanded by 45% over the past ten years. Oncology research and development activity remains concentrated on targeted therapies, which made up 90% of the late phase pipeline in 2016. Focus is being placed on targeted therapies that use genetic marker tests to indicate a greater likelihood of tumour response, or amplify the patient’s own immune response to target the cancer. The late phase oncology pipeline includes 278 biologic therapies, including 15 gene therapies, 133 new monoclonal antibodies (mAbs), and 14 biosimilars of existing mAbs. The late phase pipeline also includes 82 potential vaccines for a wide variety of tumour types. Immunotherapies are one of the fastest growing areas within oncology R&D, and will undoubtedly make up a larger portion of the pipeline in 2021.

  • Alkylating Agents
  • Anthracyclines
  • Cytoskeletal Disruptors (Taxanes)
  • Epothilones
  • Histone Deacetylase Inhibitors
  • Inhibitors of Topoisomerase I
  • Inhibitors of Topoisomerase II
  • Kinase Inhibitors
  • Nucleotide Analogs & Precursor Analogs
  • Peptide Antibiotics
  • Platinum-based Agents
  • Retinoids
  • Vinca Alkaloids & Derivatives

Related Conference of Chemotherapeutic Agents

September 23-24, 2025

10th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
September 24-25, 2025

5th World Congress on Rare Diseases & Orphan Drugs

Aix-en-Provence, France
October 23-24, 2025

21st Annual Meet on Pharmaceutical Sciences

Paris, France
November 11-12, 2025

6th Annual Congress on Antibiotics and Bacterial Infections

Amsterdam, Netherlands
November 13-14, 2025

21st International Conference on Pharmaceutical Chemistry

Aix-en-Provence, France
November 20-21, 2025

21st Annual Congress on Pharmacology and Toxicology

Paris, France
November 27-28, 2025

4th World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 27-28, 2025

4th World Congress on Precision and Personalized Medicine

Zurich, Switzerland
December 01-02, 2025

13th International Conference on Clinical Trials

Vancouver, Canada
February 23-24, 2026

3rd World Congress on Biologics and Biosimilars

London, UK
March 23-24, 2026

36th Annual European Pharma Congress

London, UK
April 16-17, 2026

19th European Biosimilars Congress

Rome, Italy
April 27-28, 2026

9th European Biopharma Congress

Paris, Aland Islands
May 28-29, 2026

3rd International Conference on Pharmacognosy

Madrid, Spain
July 27-28, 2026

39th World Congress on Pharmacology

Rome, Italy

Chemotherapeutic Agents Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in